Edesa Biotech (EDSA) vs SCYNEXIS (SCYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Edesa Biotech (EDSA) has outperformed SCYNEXIS (SCYX) over the past year, gaining 34.6% versus a loss of 32.1%. Over five years, SCYX leads with a -90.5% price change compared with -93.3% for EDSA. Edesa Biotech is the larger company by market cap ($47.7 million vs $41.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDSA | SCYX |
|---|---|---|
| Share price | $3.53 | $4.12 |
| Market cap | $47.70M | $40.99M |
| 1-day change | -3.42% | -2.37% |
| YTD return | +157.75% | -16.53% |
| 1-year return | +34.56% | -32.11% |
| 5-year return | -93.31% | -90.53% |
| EPS (TTM) | $-1.72 | $-0.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.32 | $9.12 |
| 52-week low | $0.72 | $3.53 |
| Distance from 52-week high | -82.63% | -54.82% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +362.59% | +781.80% |
| Average volume | 61.89K | 279.10K |
| Shares outstanding | 13.51M | 9.95M |
| Employees | 17 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed SCYX by 66.7 percentage points over the past year.
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About SCYNEXIS
SCYX stock →SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
EDSA vs SCYX FAQ
Which is bigger, Edesa Biotech or SCYNEXIS?
Edesa Biotech (EDSA) is larger, with a market capitalization of $47.70M compared with $40.99M for SCYNEXIS (SCYX).
Which stock has performed better over the past year, EDSA or SCYX?
EDSA returned +34.56% over the past 12 months, compared with -32.11% for SCYX (price return, excluding dividends). Past performance does not predict future results.
Are Edesa Biotech and SCYNEXIS in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.